InflaRx N.V. IFRX 深 沪
等待开盘 04-01 09:30:00 美东时间
0.8944
+0.063
+7.54%
华盛通- 最 高0.898
- 今 开0.84
- 成交量 17.18万股
- 最 低 0.8387
- 昨 收 0.8317
- 总市值 6059.30万
- 52周最高 1.94
- 市盈率 静 --
- 换手率 0.25%
- 52周最低 0.7113
- 委 比 99.70%
- 总股本 6774.71万
- 历史最高 53.10
- 量 比 0.52
- 振 幅 7.13%
- 历史最低 0.7113
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InflaRx Highlights Data From Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum At 2026 AAD Annual Meeting
InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab in pyoderma
03-30 19:40
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
InflaRx N.V. announced positive Phase 3 results for vilobelimab in pyoderma gangrenosum (PG), presented at the 2026 AAD Annual Meeting. The study showed higher rates of complete remission (20.8% vs. 5.1%) and target ulcer closure (20.8% vs. 16.7%) compared to placebo, with a favorable safety profile. Vilobelimab significantly reduced C5a levels and ulcer volume. Despite early termination due to futility, the data suggest potential for treating C5...
03-30 11:30
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
Guggenheim Maintains Buy on InflaRx, Lowers Price Target to $14
Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $22 to $14.
03-20 20:43
InflaRx Q4 EPS $(0.17) Beats $(0.18) Estimate, Sales $(39.501K) Miss $230.000K Estimate
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 88.89 percent decrease over losses of $(0.09) per share from the same
03-19 19:45
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
InflaRx receives Nasdaq notification
InflaRx (IFRX) said on Friday it had received a notice from Nasdaq for failing to meet the $1 minimum bid price requirement after its shares closed below that level for 30 consecutive business days. T...
03-14 05:09
InflaRx Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the "Notice"), dated March 11,
03-14 05:05
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
InflaRx N.V. received a notice from Nasdaq regarding its ordinary shares trading below the minimum $1.00 bid price requirement for 30 consecutive business days. The company has 180 days until September 7, 2026, to regain compliance. If unsuccessful, it may transfer to the Nasdaq Capital Market, extending the compliance period by another 180 days until March 8, 2027. The notice does not affect current listing, and the company plans to monitor its ...
03-13 21:00
InflaRx to Report Full Year 2025 Results on March 19, 2026
InflaRx N.V. announced it will release its 2025 fourth-quarter and full-year financial and operational results on March 19, 2026, without a conference call. The company focuses on developing anti-inflammatory therapies targeting the complement system, with lead programs izicopan for hidradenitis suppurativa and vilobelimab, an anti-C5a monoclonal antibody. Founded in 2007, InflaRx operates globally with offices in Germany and the U.S.
03-12 11:30
